Expression mapping at 12p12-13 in advanced prostate carcinoma

International Journal of Cancer

Volumn 109, Issue 5, 2004, Pages 668-672

  Kibel, Adam S ^a   Huagen, John ^a   Guo, Chan ^a   Isaacs, William B ^b   Yan, Yan ^a   Pienta, Kenneth J ^c   Goodfellow, Paul J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

12p12 13; DNA analysis; Genetics; Loss of heterozygosity; Prostatic neoplasm; RNA analysis

Indexed keywords

DNA; RNA;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CHROMOSOME 12P; CONTROLLED STUDY; DNA SEQUENCE; GENE; GENE MAPPING; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CELL LINE, TUMOR; CHROMOSOME DELETION; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 13; DISEASE PROGRESSION; DNA METHYLATION; DNA, NEOPLASM; DOWN-REGULATION; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOSS OF HETEROZYGOSITY; LYMPHATIC METASTASIS; MALE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TRANSPLANTATION, HETEROLOGOUS;

EID: 1642501545     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20060     Document Type: Article

References (38)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Kunimi K, Bergerheim US, Larsson IL, Ekman P, Collins VP. Allelotyping of human prostatic adenocarcinoma. Genomics 1991;11: 530-6.
3. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, Isaacs WB. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993;53:3869-73.
4. Sakr WA, Macoska JA, Benson P, Grignon DJ, Wolman SR, Pontes JE, Crissman JD. Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res 1994;54:3273-7.
5. Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995;55:342-7.
6. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996;56:3091-102.
7. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998;153:141-8.
8. Morton RA, Ewing CM, Nagafuchi A, Tsukita S, Isaacs WB. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells. Cancer Res 1993;53:3585-90.
9. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer, Science 1997;275:1943-7.
10. Voeller HJ, Augustus M, Madike V, Bova GS, Carter KC, Gelmann EP, Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res 1997;57: 4455-9.
11. Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Martignetti JA, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001;294:2563-6.
12. Kibel AS, Schutte M, Kern SE, Isaacs WB, Bova GS. Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Res 1998;58:5652-5.
13. Kibel AS, Faith DA, Bova GS, Isaacs WB. Loss of heterozygosity at 12p12-13 in primary and metastatic prostate adenocarcinoma. J Urol 2000;164:192-6.
14. Kibel AS, Freije D, Isaacs WB, Bova GS. Deletion mapping at 12p12-13 in metastatic prostate cancer. Genes Chromosomes Cancer 1999;25:270-6.
15. Golub TR. TEL gene rearrangements in myeloid malignancy. Hematol Oncol Clin North Am 1997;11:1207-20.
16. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998;18:184-7.
17. KIp1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998;90:1284-91.
18. KIp1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998;90:916-20.
19. Kibel AS, Faith DA, Bova GS, Isaacs WB. Mutational analysis of ETV6 in prostate carcinoma. Prostate 2002;52:305-10.
20. kIp1 in prostate carcinoma. Prostate 2001;48:248-53.
21. Montpetit A, Boily G, Sinnett D. A detailed transcriptional map of the chromosome 12p12 tumour suppressor locus. Eur J Hum Genet 2002; 10:62-71.
22. Baens M, Wlodarska I, Corveleyn A, Hoornaert I, Hagemeijer A, Marynen P. A physical, transcript, and deletion map of chromosome region 12p12.3 flanked by ETV6 and CDKN1B: hypermethylation of the LRP6 CpG island in two leukemia patients with hemizygous del(12p). Genomics 1999;56:40-50.
23. NCBI MapViewer, Build 33. http://www.ncbi.nlm.nih.gov/mapview/maps.cgi, accessed August 12, 2003.
24. Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler SA, Curtis D, Lange PH. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 1996;2:1039-48.
25. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3:402-8.
26. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kong HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56:3042-6.
27. Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI, Bodner DR, Jacobberger JW, Delmoro CM, Giaconia JM, Pretlow TP. Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst 1993;85:394-8.
28. Hoornaert I, Marynen P, Baens M. CREBL2, a novel transcript from the chromosome 12 region flanked by ETV6 and CDKN1B. Genomics 1998;51:154-7.
29. Lee SL, Wang Y, Milbrandt J. Unimpaired macrophage differentiation and activation in mice lacking the zinc finger transplantation factor NGFI-A (EGR1). Mol Cell Biol 1996;16:4566-72.
30. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 1997;22:130-9.
31. Morrison TB, Weis JJ, Wittwer CT. Quantification of low-copy transcripts by continuous SYBR green I monitoring during amplification. Biotechniques 1998;24:954-8, 960, 962.
32. Aissani B, Sinnett D. Fine physical and transcript mapping of a 1.8 Mb region spanning the locus for childhood acute lymphoblastic leukemia on chromosome 12p12. Gene 1999;240:297-305.
33. CGAP. http://cgap.nci.nih.gov, accessed August 12, 2003.
34. Guo B, Godzik A, Reed JC. Bcl-G, a novel pro-apoptotic member of the Bcl-2 family. J Biol Chem 2001;276:2780-5.
35. Masuda K, Shima H, Watanabe M, Kikuchi K. MKP-7, a novel mitogen-activated protein kinase phosphatase, functions as a shuttle protein. J Biol Chem 2001;276:39002-11.
36. Tanoue T, Yamamoto T, Maeda R, Nishida E. A novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38 alpha and beta MAPKs. J Biol Chem 2001;276:26629-39.
37. Unigene. http://www.ncbi.nlm.nih.gov/UniGene, accessed August 12, 2003.
38. BLAST. http://www.ncbi.nlm.nih.gov/BLAST/ accessed August 12, 2003.